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Abstract A sensitive method was developed for quantify-
ing a wide range of cannabinoids in oral fluid (OF) by liquid
chromatography–tandem mass spectrometry (LC–MS/MS).
These cannabinoids include D9-tetrahydrocannabinol (THC),
11-hydroxy-D9-tetrahydrocannabinol (11-OH-THC), 11-nor-
9-carboxy-D9-tetrahydrocannabinol (THCCOOH), cannabinol
(CBN), cannabidiol (CBD), D9-tetrahydrocannabinolic acid
A (THC-A), 11-nor-9-carboxy-D9-tetrahydrocannabinol
glucuronide (THCCOOH-gluc), and D9-tetrahydrocannabi-
nol glucuronide (THC-gluc). Samples were collected using a
QuantisalTM device. The advantages of performing a liquid–
liquid extraction (LLE) of KCl-saturated OF using heptane/
ethyl acetate versus a solid-phase extraction (SPE) using
HLB copolymer columns were determined. Chromato-
graphic separation was achieved in 11.5 min on a KinetexTM
column packed with 2.6-lm core–shell particles. Both
positive (THC, 11-OH-THC, CBN, and CBD) and negative
(THCCOOH, THC-gluc, THCCOOH-gluc, and THC-A)
electrospray ionization modes were employed with multiple
reaction monitoring using a high-end AB Sciex API 5000TM
triple quadrupole LC–MS/MS system. Unlike SPE, LLE
failed to extract THC-gluc and THCCOOH-gluc. How-
ever, the LLE method was more sensitive for the detection
of THCCOOH than the SPE method, wherein the limit
of detection (LOD) and limit of quantification (LOQ)
decreased from 100 to 50 pg/ml and from 500 to 80 pg/ml,
respectively. The two extraction methods were successfully
applied to OF samples collected from volunteers before and
after they smoked a homemade cannabis joint. High levels of
THC were measured soon after smoking, in addition to sig-
nificant amounts of THC-A. Other cannabinoids were found
in low concentrations. Glucuronide conjugate levels were
lower than the method’s LOD for most samples. Incubation
studies suggest that glucuronides could be enzymatically
degraded by glucuronidase prior to OF collection.
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Introduction
Cannabis is one of the most widely used illicit drugs in the
world. It is often implicated in forensic cases, such as drug-
addiction deaths, driving under the influence of drugs,
accidents, and others. The major psychoactive constituent
of cannabis smoke is D9-tetrahydrocannabinol (THC). THC
is frequently detected in the blood of drivers involved or
killed in traffic accidents or suspected of driving while
impaired. Impairment can result in a loss of tracking
ability, attention, reaction time, hand–eye coordination,
vigilance, and perception of time and distance [1]. There-
fore, sensitive and accurate methods for determining
whether someone is under the influence of cannabis are
necessary. One may also need to determine whether the use
of cannabis occurred shortly before a legally significant
event. To this end, one approach could be the detection of
cannabinoids in oral fluid (OF). OF is a mixture of saliva
from the salivary glands, mucosal cells, bacteria, and food
debris containing several hydrolysis enzymes.
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THC is sequestered in the oral cavity during cannabis
smoking. After smoking, much lower concentrations of
THC are transferred from the plasma to the oral fluid [2].
Therefore, the measurement of high levels of THC in OF
strongly suggests recent cannabis use and indicates that the
smoker is under the influence of cannabis. This assumption
can be confirmed with a second-stage blood analysis. The
advantages of using OF over other matrices for monitoring
cannabis consumption were recently detailed by Choo and
Huestis [2]: OF offers noninvasive collection and a reduced
risk of adulteration. Furthermore, collection can be per-
formed without medical supervision and is less objection-
able to patients. However, there is a significant issue with
OF collection for cannabis testing because the drug is
known to cause dry mouth, and for this reason, the speci-
men volume may be limited [3]. Several cannabinoids have
been detected in OF, but apart from THC, they have always
been found in low concentrations, especially the metabo-
lites of THC. Because THC can also be detected after
passive exposure, the detection of THC metabolites (e.g.,
11-nor-9-carboxy-D9-tetrahydrocannabinol, THCCOOH)
indicative of active smoking is of prime importance [4].
Cannabinol (CBN), the primary degradation product of
THC, and cannabidiol (CBD), another component of can-
nabis smoke, have also been detected in OF [5–7]. The
incubation of saliva with glucuronidase enzymes resulted
in an increase in the concentrations of free cannabinoids,
suggesting that significant levels of conjugated metabolites
are also present in this matrix. The question of whether D9-
tetrahydrocannabinolic acid A (THC-A), the pyrolytic
precursor of THC, can be used as a marker of active and
recent cannabis smoking remains to be answered [8].
Furthermore, it is useful to distinguish between a thera-
peutic ingestion of THC (e.g., Sativex, Marinol) and the
inhalation of a cannabis joint. In this context, it has been
shown that THC was not detected in OF when capsules of
Marinol were rapidly swallowed [7], however it is unclear
if the same applies to capsules that are chewed before being
swallowed.
Several methods have been proposed for the analysis of
cannabinoids in alternative matrices (bile, meconium)
[9–17] as well as in oral fluid [18–28]. To our knowledge,
none allows the sensitive quantification of a broad range of
molecules, including the acid precursors, metabolites, and
the conjugates. The aim of this study was to devise an
analytical method for the rapid and unequivocal determi-
nation of THC, 11-hydroxy-D9-tetrahydrocannabinol
(11-OH-THC), THCCOOH, THC-A, CBN, CBD, 11-nor-
9-carboxy-D9-tetrahydrocannabinol glucuronide (THC-
COOH-gluc), and D9-tetrahydrocannabinol glucuronide
(THC-gluc) in OF samples by liquid chromatography–
tandem mass spectrometry (LC–MS/MS). To this end, we
used an unconventional KinetexTM [29, 30] column packed
with 2.6-lm core–shell particles coupled with a high-end and
sensitive AB Sciex Triple Quadrupole API 5000TM mass
spectrometer. Two types of extraction methods—liquid–
liquid (LLE) and solid-phase (SPE) extraction—were
tested with the goal of measuring the free cannabinoids and
glucuronide conjugates concentrations and to achieve sub-
nanogram range detection levels. Whatever the conditions
tested, the LLE method failed to extract the glucuronide
conjugates from the OF collected using the QuantisalTM
device. A more versatile SPE technique was therefore
developed to analyze the entire panel of cannabinoids.
Experimental
Chemicals and materials
THC, 11-OH-THC, THCCOOH, CBN, CBD, THC-A,
THCCOOH-gluc, and the internal standards THC-d3,
11-OH-THC-d3, and THCCOOH-d9 were purchased from
Cerilliant (Round Rock, TX, USA). THC-gluc was
obtained from ElSohly Laboratories (Oxford, MS, USA).
Cannabichromene (CBC) was purchased from BGB
Analytik (Boeckten, Switzerland).
Oasis HLB (3 cc/60 mg) extraction cartridges were
purchased from Waters (Baden, Switzerland). Acetonitrile
(ACN) and methanol (MeOH) were purchased from
Sigma-Aldrich (Steinheim, Germany). All other chemicals
were puriss grade. Drug-free OF was composed of a mix-
ture of OF samples obtained by spitting from several
coworkers who had fasted and did not consume cannabis.
OF was collected with the QuantisalTM device (nal von
minden GmbH, Regensburg, Germany), which consists of
an absorptive cellulose pad mounted on a polypropylene
stem. The volume indicator turns blue when an adequate
volume (1.0 ± 10 % ml) is collected. The pad was then
placed into a plastic tube containing 3 ml of buffer. As
recommended by the supplier, the tube was capped and left
at room temperature overnight and then stored at -80 C
prior to analysis. Moore et al. [31] recommended storing
the OF samples in the QuantisalTM collection device under
refrigeration to inhibit THC degradation. For better pres-
ervation, the QuantisalTM devices were stored at -80 C
prior to analysis.
Preparation of standard solutions
Individual stock solutions of 10 lg/ml THC, THCCOOH,
THC-A, CBD, and CBN and 1 lg/ml THCCOOH-gluc,
11-OH-THC, and THC-gluc were diluted with methanol to
prepare calibration standards for LLE and SPE methods.
Individual intermediate stock solutions containing 200 and
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10 ng/ml of each cannabinoid were prepared in methanol
and stored at -20 C. A specific solution of THCCOOH
was prepared at a concentration of 1 ng/ml in methanol for
the LLE method. In addition, a 2 ng/ml solution of THC-
COOH-d9 and a 100 ng/ml solution of THC-d3 and 11-OH-
THC-d3 were prepared for the LLE method. A 100-ll
aliquot of the THCCOOH-d9 solution and 50 ll of the
THC-d3 and 11-OH-THC-d3 solution were added to the
QuantisalTM buffer (final concentrations in the extraction
buffer: 50 pg/ml of THCCOOH-d9 and 1250 pg/ml of
THC-d3 and 11-OH-THC-d3). For the SPE method, an
internal standard solution containing 100 ng/ml of THC-d3,
11-OH-THC-d3, and THCCOOH-d9 was prepared in
methanol. Fifty microliters of this mix was added to the
QuantisalTM collection buffer before extraction (final
concentrations 1250 pg/ml). THC-d3 was utilized for CBN,
CBD, and THC-gluc determination, whereas THCCOOH-
d9 was used for the quantification of THC-A and THC-
COOH-gluc. Other cannabinoids were measured in the
presence of their deuterated homologs as internal stan-
dards. A specific solution of 100 ng/ml of CBC was
prepared from a standard solution at a concentration of
1 lg/ml.
Sample pretreatment
The maximum volume of absorbed OF was collected by
squeezing the cellulose pad from the QuantisalTM collec-
tion device onto the walls of the plastic tube. Subsequently,
methanol (1.5 ml) was added to the pad to wash off any
residual cannabinoids. The methanolic extract was evapo-
rated to dryness under nitrogen at room temperature. The
OF–buffer mixture was added to the methanolic residue
and the resulting mixture was sonicated for 5 min. The
combined extracts were then purified by liquid–liquid or
solid-phase extraction.
Liquid–liquid extraction (LLE)
A 1.5-ml aliquot of OF combined extracts was mixed with
0.5 ml of ammonium formate buffer (10 mM, pH 6.5).
Subsequently, potassium chloride was added until the
solution became saturated. Samples were extracted with
4 ml of heptane:ethyl acetate (4:1, v/v) using a vortex
shaker for 1 min, followed by 5 min on a reciprocating
shaker (Edmond Bu¨hler SM-30, GlasKeller, Basel; 180
oscillations/min). After centrifugation at 3000 rpm for
5 min, the organic phase was removed and evaporated to
dryness under nitrogen at room temperature. The residue
was then dissolved in 100 ll of initial mobile phase (70:30,
A:B, see below), vortexed, sonicated for 5 min, and
transferred to a 250-ll vial for LC–MS/MS analysis.
Solid-phase extraction (SPE)
Oasis HLB extraction columns were conditioned with 2 ml
of methanol, 2 ml of deionized water, and 2 ml of
ammonium formate buffer (10 mM, pH 6.5). Subsequently,
1.5 ml of combined OF extracts was added to the extrac-
tion column and loaded by gravity. The columns were
washed with 4 ml of ammonium formate buffer (10 mM,
pH 6.5):methanol (95:5, v/v) and dried under vacuum for
15 min. Cannabinoids were eluted with 3 ml of methanol
(2 9 1.5 ml) and the resulting eluates were evaporated to
dryness under a nitrogen stream at room temperature. The
residues were reconstituted in 100 ll of initial mobile
phase, vortexed, sonicated for 5 min, and transferred into
250-ll autosampler vials for LC–MS/MS analysis.
Liquid chromatography
Chromatographic analyses were carried out using a Dionex
UltiMate 3000 Rapid Separation LC system equipped with
two binary pumps, an autosampler, and a column oven
compartment (Thermo Scientific, Olten, Switzerland).
A KinetexTM C18 100A column (150 9 2.1 mm i.d.)
(Phenomenex, Brechbu¨hler, Echallens, Switzerland) packed
with core–shell 2.6 lm particles was used for the chromato-
graphic separation. The autosampler and column oven tem-
peratures were set to 10 and 40 C, respectively. A 10-ll
sample was injected into the LC–MS/MS. Gradient elution
was performed using a mixture of (A) ammonium formate
buffer (5 mM, pH 6.8) and (B) acetonitrile at a constant flow
rate of 400 ll/min. The initial gradient conditions were 30 %
B, held for 30 s, and then linearly increased to 90 % B over
7 min. The final B concentration was maintained for 2 min.
Finally, the proportion of solvent B was reduced from 90 to
30 % over 30 s and held for 1.5 min. The maximum pressure
was set to 600 bar.
Mass spectrometry
The LC system was coupled to an AB Sciex API 5000TM
triple quadrupole mass spectrometer interfaced with a Turbo
VTM source with a TurboIonSpray probe (ESI). Both posi-
tive and negative polarities were employed: THCCOOH,
THCCOOH-gluc, THC-gluc, and THC-A were monitored in
the negative ionization mode, whereas THC, 11-OH-THC,
CBD, and CBN were monitored in the positive ionization
mode. Mass spectrometry transitions were recorded using a
scheduled multiple reaction monitoring mode (MRM) with
three separate time windows. The first time window (from
start to 5.1 min) was operated in the negative ionization
mode, whereas the second (from 5.1 to 6.4 min) and the third
(from 6.4 to 7.5 min) were operated in the positive mode. The
selected ions, MS/MS parameters and retention times are
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provided in Table 1. The ion spray voltage was set to
-4500 V for the negative polarity and ?5500 V for the
positive polarity. The source temperature was set to 550 C
for both cases. Analyst 1.6 software was used to control the
instrument and process the data. A representative recon-
structed MRM chromatogram of an OF extract spiked with
50 ng/ml of each cannabinoid is shown in Fig. 1.
Method validation
Method validation was performed by establishing linearity,
intraday and intermediate precisions, trueness and bias,
limit of detection (LOD), limit of quantification (LOQ),
extraction recovery, and matrix effects. In addition, the
stability of the cannabinoids during storage was assessed.
The validation was performed according the Socie´te´
Franc¸aise des Sciences et Techniques Pharmaceutiques
(SFSTP) recommendations [32, 33].
Sensitivity, limits of detection and quantification
The LOD was determined in triplicate by injecting a series
of drug-fortified human OF extracts in order of decreasing
concentration. The LOD was the lowest analyte concen-
tration that exhibited a signal-to-noise (S/N) ratio of at least
3 and an acceptable chromatographic peak shape. The LOQ
was the lowest concentration that exhibited acceptable
accuracy and precision [relative standard deviation (RSD)
within at least 20 %, n = 4].
Linearity, trueness and bias, intraday and intermediate
precisions
The linearity of the response function was investigated in
the OF concentration range of 0.5–75 ng/ml for all can-
nabinoids, and in the range of 50–500 pg/ml for THC-
COOH with the LLE method. Calibration curves were
obtained at eight calibration levels by injecting 0.1, 0.5, 1,
5, 10, 25, 50, and 100 ng (30, 50, 100, 250, 500, 750, 1000,
and 1500 pg of THCCOOH with LLE) of standards
directly onto the pad before adding 1 ml of drug-free OF.
Linearity was investigated by calculating the regression
using the least-squares method and is expressed as the
square of the correlation coefficient (R2). A weighting
factor of 1/x was applied for each compound. Calibration
curves obtained on three different days were used to
Table 1 Selected ion parameters and retention times for cannabinoids in oral fluid
Compound name Precursor ion (m/z) Product ions (m/z) DP (V) CE (V) RT (min) TWa
THCCOOH-gluc 519.2 343.2 -25 -30 3.24 1
519.2 299.2 -25 -38 3.24 1
THC-gluc 489.0 313.2 -50 -42 3.31 1
489.0 113.2 -50 -30 3.31 1
THC-A 357.1 313.2 -35 -28 4.68 1
357.1 245.0 -35 -36 4.68 1
THCCOOH 343.2 299.2 -50 -24 4.87 1
343.2 191.1 -50 -42 4.87 1
11-OH-THC 331.3 313.2 36 21 5.25 2
331.3 193.1 36 33 5.25 2
CBD 315.2 193.2 41 29 6.13 2
315.2 259.1 41 25 6.13 2
CBN 311.2 223.2 51 27 6.68 3
311.2 178.2 51 81 6.68 3
THC 315.2 193.1 41 29 7.02 3
315.2 259.1 41 25 7.02 3
THC-d3 318.2 262.1 41 25 7.00 3
318.2 196.1 41 31 7.00 3
11-OH-THC-d3 334.3 316.0 31 21 5.23 2
334.3 196.0 31 33 5.23 2
THCCOOH-d9 352.2 308.1 -50 -24 4.84 1
352.2 194.2 -50 -44 4.84 1
Boldface denotes quantifier transitions
DP declustering potential, CE collision energy, RT retention time, TW time window
a TW 1 from start to 5.1 min, TW 2 from 5.1 to 6.4 min and TW 3 from 6.4 to 7.5 min
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calculate the mean slope, the y intercept, and their varia-
tions. Bias and precisions were determined at five con-
centration levels across the linear dynamic range. The
intraday precision was evaluated by analyzing four OF
specimens spiked with 0.5, 2, 10, 30, and 75 ng/ml (50, 75,
100, 250, 500 pg/ml for THCCOOH by LLE) concentra-
tions of cannabinoids on the same day. The intermediate
precision was assessed by evaluating the same concentra-
tion on three separate days. The bias was determined by
comparing the mean measured concentration of four ana-
lytes with that of the target value and was expressed as a
percentage of the target concentration. Acceptable values
were within 15 % of the target concentration for the bias
and less than 15 % for the coefficients of variation (CVs)
of the intraday and intermediate precisions.
Selectivity, interferences, extraction recovery, and matrix
effects
Ten blank OF extracts of different sources were analyzed
to prove the lack of response in blank matrix. Furthermore,
possible interferences were tested with CBC. This can-
nabinoid, THC, and CBD are characterized by the same
mass weight and share a few common ion transitions. It is
therefore important that these cannabinoids are well sepa-
rated from each other. Their unequivocal identification
relies on both their ion transitions and their retention time
(RT). To disclose any interference, CBC standards were
either injected alone or in combination with CBD and THC
standards to compare their RT and to determine whether
CBC could interfere with CBD and THC quantitation.
The extraction recoveries and matrix effects were
determined for each analyte at low and high concentrations
according to the method proposed by Matuszewski et al.
[34]. Three batches of OF samples were analyzed: batch A
was composed of drug-free OF samples spiked with can-
nabinoids prior to SPE or LLE; batch B was composed of
OF extracts spiked after SPE or LLE; batch C was com-
posed of standard methanolic solutions of cannabinoids.
Following analysis by LC–MS/MS, the cannabinoid peak
areas were determined. The A/B ratio gave the extraction
recovery, whereas the B/C ratio gave the matrix effect.
Stability studies and carryover
The stability of OF samples was investigated after one and
three freeze–thaw cycles (23 h freezing at -80 C fol-
lowed by 1 h thaw at room temperature). Extracts of OF
samples (n = 4) at three fortified concentrations (2, 10, and
75 ng/ml of OF) were analyzed before and after one or
three freeze–thaw cycles. The response (peak areas) was
compared to that of the unfrozen samples (0 % loss) and
calculated as a loss percentage.
The stability of cannabinoids at room temperature was
also investigated. After OF collection, the collector device
was left at room temperature for 1, 4, 12, or 24 h before
storage at -80 C. The carryover was established by
injecting one extract prepared with one OF sample
Fig. 1 Representative
reconstructed MRM
chromatogram of an OF sample
spiked at a concentration of
50 ng/ml for each cannabinoid:
(1) THCCOOH-gluc 519.2
? 343.2, (2) THCCOOH-gluc
519.2 ? 299.2, (3) THC-gluc
489.0 ? 313.2, (4) THC-gluc
489.0 ? 113.2, (5) THC-A
357.1 ? 313.2, (6) THC-A
357.1 ? 245.0, (7) THCCOOH
343.2 ? 299.2 (8) THCCOOH
343.2? 191.1, (9) 11-OH-THC
331.3 ? 313.2, (10) 11-OH-
THC 331.3 ? 193.1, (11) CBD
315.2 ? 193.2, (12) CBD 315.2
? 259.1, (13) CBN 311.2
? 223.2, (14) CBN
311.2 ? 178.2, (15) THC
315.2 ? 193.2, (16) THC 315.2
? 259.1. Vertical lines indicate
the three time windows (TW).
First TW: negative mode.
Second and third TW: positive
mode
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containing the highest concentration investigated followed
by a blank extract. The carryover was considered insig-
nificant when the peak area was \20 % of the lower limit
of quantification.
Determination of cannabinoids in oral fluid sampled
from five volunteers before and after smoking
a homemade joint
Five healthy male volunteers between 18 and 30 years of
age, all heavy cannabis smokers, participated in the study.
Subjects were recruited through advertisements in hospitals
and universities. They had no known history of neurolog-
ical or psychiatric disorders. The inclusion protocol con-
sisted of several distinct steps: during a first interview, we
gave detailed explanations about the experimental proto-
col. Subjects then underwent a thorough medical exami-
nation and a psychiatric interview. During this inclusion
visit, participants provided a detailed medical history and
filled out a questionnaire about their drug use and habits.
The mean consumption of cannabis for the 3 months pre-
ceding inclusion in the study was set to a minimum of ten
joints per month and a maximum of two joints per day.
Subjects were asked to provide several OF specimens
before and after smoking a homemade cannabis joint. The
sampling of the OF specimens was carried out at home under
real-life conditions. The study was approved by the Cantonal
Research Ethics Committee (Vaud), and the volunteers were
asked to provide their informed consent. All subjects were
financially compensated for their participation. One OF
sample was collected before smoking the joint, and then five
or six were collected afterwards. For practical reasons, the
study was terminated 4 h after the joint was smoked. After
collection, the samples were brought to the laboratory and
stored at -80 C prior to analysis.
Chemical and enzymatic hydrolysis of glucuronides
in OF
Several publications have shown that saliva contains beta-
glucuronidase enzymes [35–37]. To investigate whether
these OF enzymes are able to hydrolyze cannabinoid
conjugates, the degree of degradation of two glucuronides
was evaluated under various conditions to discriminate
between nonenzymatic (chemical) and enzymatic hydro-
lysis. Hydrolysis was carried out in water or OF—at the
native OF pH (pH 7.0) and also at the optimal pH for beta-
glucuronidase activity (pH 4.5). We also assessed the effect
of heat inactivation of OF enzymes on the degradation of
cannabinoid conjugates. To this end, 300 ll of water or
acetate buffer (200 mM, pH 4.5) was added to 2.5 ml of
water, native OF, or inactivated OF (obtained by boiling
for 5 min). All experiments were repeated three times.
Samples containing THC-gluc and THCCOOH-gluc at
concentrations of 5 ng/ml each were incubated at 37 C for
up to 5 h. Aliquots were sampled at t = 0, 0.5, 1, and 5 h.
Solid-phase extraction and LC–MS/MS analysis were
carried out according to the developed method.
Results and discussion
Extraction
All free unconjugated cannabinoids were detected by both
the LLE and SPE methods. However, even after changing
the extraction conditions, neither THC-gluc nor THC-
COOH-gluc could be detected using the LLE technique.
Increasing the polarity of the extracting solvent or adding
different salts to the water phase did not significantly
increase the recovery of the glucuronide derivatives.
Although a higher sensitivity was achieved for THCCOOH
using the LLE approach, the SPE method allowed for the
analysis of the glucuronide conjugates. Because each
method has its own advantages and limitations, both were
validated.
Method validation
The main validation parameters obtained for the LLE and
SPE extraction methods are provided in Tables 2 and 3,
respectively.
Limits of detection and quantification
The sensitivities of the LLE and SPE methods were esti-
mated by determining the LOD and LOQ values. The
concentration that satisfied the validation criteria (CV
\20 % for the bias and precision values) for the LOQ was
0.5 ng/ml for all cannabinoids using both extraction
methods, except for THCCOOH, which exhibited a LOQ
of 0.08 ng/ml with the LLE method. Moore et al. [4] and
Day et al. [21] reported concentrations of THCCOOH in
OF in the range of 5–150 pg/ml, which includes the LOQ
value of the LLE method. These concentration thresholds
are consistent with the values discussed by Pil and Ver-
straete [38] in their review of drug testing in oral fluid.
Linearity, trueness and bias, intraday and intermediate
precisions
The range of the standard curves was 0.5–75 ng/ml for all
cannabinoids investigated, with the exception of THC-
COOH extracted by LLE, which was 50–500 pg/ml. The
R2 values (with 1/x weighting) were acceptable for all
cannabinoids (R2 [ 0.9943). Variations in the slopes of all
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calibration curves were \10 % and the intercept value did
not differ significantly from 0 (P \ 0.05). For concentra-
tions higher than the LOQ, the variation coefficients of
intraday and intermediate precisions were B15 %. The
trueness values were within 91.2 and 113 % for the SPE
technique and within 98.5 and 114.5 % for the LLE
method.
Selectivity, interferences, extraction recovery, and matrix
effects
Oral fluid specimens collected from drug-free individuals
showed no interference with the assay. For interferences
with minor cannabinoids, CBC was analyzed by infusion in
order to determine its ion transitions. As expected, they
were identical to those selected for THC and CBD. CBC
standards were then injected in the LC–MS/MS. No over-
lap could be observed. The RT of CBC was 7.24 min while
those of THC and CBD were 7.02 and 6.13 min, respec-
tively. This result confirms a previous study of Hazekamp
et al. [39]. In 2005, they studied the chromatographic and
spectroscopic data of a wide range of cannabinoids. They
found that CBC, CBD, and THC were well separated with
a reversed-phase C18 column whatever the pH used, acid
or basic. More recently, Poklis et al. [40] showed that the
RTs of CBC, CBD, and THC were well separated by
reversed-phase chromatography. Because CBC, CBD, and
THC are well separated, misidentification of one of these
compounds cannot occur. Furthermore, in 1984, Barni-
Comparini et al. [41] studied the cannabinoid levels in 176
plants of different lots of Cannabis sativa L. They showed
that CBC was present only in tiny amounts in the leaves;
the maximum concentration was around 0.5 % based on
dry weight, suggesting that chromatographic interferences
are unlikely.
The extraction efficiencies and matrix effects, expressed
as percentages, for each cannabinoid at two concentrations
are provided in Tables 4 and 5. Each result is an average of
four independent determinations; standard deviations are
indicated in brackets. The recovery of cannabinoids was
relatively low with the LLE method (approximately 42 %)
and ranged between 39.6 % for THC and 47.1 % for CBN.
The extraction yield for all cannabinoids remained rela-
tively constant across the range of concentrations tested.
Table 2 Validation data for trueness, intraday and intermediate precisions, and linearity for THCCOOH, THC-A, 11-OH-THC, CBD, THC,
and CBN obtained using the liquid–liquid extraction method
Validation criterion Levela a THCCOOH Levela b THC-A 11-OH-THC CBD THC CBN
Trueness (%) 0.05 119.9 0.5 104.0 114.5 108.5 108.4 108.2
0.075 109.7 2 103.7 107.8 106.3 105.9 104.0
0.1 102.8 10 100.8 100.8 99.5 102.7 102.0
0.25 101.3 30 103.2 98.5 98.9 100.1 99.7
0.5 99.7 75 101.4 100.4 101.4 100.0 99.8
Intraday precision (CV, %) 0.05 57.6 0.5 14.6 7.4 9.0 7.1 7.1
0.075 13.5 2 6.5 7.0 6.4 5.1 4.7
0.1 8.3 10 6.9 3.6 4.6 2.0 2.7
0.25 5.2 30 5.6 4.0 3.3 1.3 1.6
0.5 4.0 75 2.0 1.9 4.7 0.4 1.4
Intermediate precision
(CV, %)
0.05 45.3 0.5 14.9 9.6 10.4 7.7 14.9
0.075 17.1 2 8.0 8.5 7.8 5.6 5.4
0.1 8.3 10 6.9 3.6 5.7 3.1 3.5
0.25 5.2 30 5.6 4.0 3.7 1.3 2.6
0.5 4.2 75 2.2 2.2 4.7 0.8 1.4
Linearity
Slope (CV) 0.9964
(2.3 %)
1.004
(0.5 %)
1.003
(0.2 %)
0.9964
(1.2 %)
1.0029
(0.7 %)
0.9995
(1.1 %)
y intercept (CV) 0.0034
(14.1 %)
0.0186
(10.1 %)
0.0061
(14.8 %)
0.0148
(10.7 %)
0.0905
(6.0 %)
0.0745
(3.6 %)
R2 0.9943 0.9976 0.9994 0.9973 0.9998 0.9995
LOD (ng/ml) 0.05 0.3 0.2 0.3 0.3 0.3
LOQ (ng/ml) 0.08 0.5 0.5 0.5 0.5 0.5
CV coefficient of variation
a Fortified OF concentration (ng/ml)
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However, LLE failed to extract the glucuronide conjugates
under all tested conditions. A variety of solvents were
evaluated for glucuronide conjugate extraction, including
diisopropylether [42] and ethyl acetate:hexane (1:9) acid-
ified with acetic acid [13]. The two latter conditions have
been previously used to extract THCCOOH-gluc from
urine [42], liver, bile, or kidney [13]. We were unable to
replicate these findings with OF. OF contains mucins that
form gels, which are responsible for its high viscosity [43].
These glycoproteins and the chemical additives that are
present in the extraction buffer of the QuantisalTM device
(blue dye, preservative, detergent) might hamper the LLE
extraction of the relatively polar glucuronide derivatives.
Although the extraction yields with the SPE method were
lower than those of the LLE technique, the SPE represents
a good compromise because it allows for the extraction of a
wider range of cannabinoids: CBD, THC, its acid precursor
(THC-A), its degradation product (CBN), and its primary
and secondary metabolites (11-OH-THC and THCCOOH)
and their corresponding glucuronide conjugates (THC-gluc
and THCCOOH-gluc). Washing of the pad with methanol
slightly increased the extraction yield of all cannabinoids
(approximately 10 %).
A matrix effect was observed for all cannabinoids,
resulting in an average ion suppression effect of approxi-
mately 30 % for SPE and 25 % for LLE. The blue coloring
agent that indicates the collection of 1 ml of OF was co-
extracted with the cannabinoids by the SPE method,
whereas it remained in the aqueous phase after LLE. This
could explain why the matrix effect of the SPE method
exceeded that of the LLE method. The decrease in the
signal intensity was the lowest for THC-A and the highest
for THC. Concheiro et al. [20] observed a matrix effect of
100 % (ion enhancement) and Badawi et al. [18] found an
ion suppression effect of 2.1 % for THC extracted from
OF. Although the recovery was relatively low and the
matrix effect relatively high, the LOD and LOQ values
achieved could be considered excellent to fair for all
cannabinoids.
Stability studies and carryover
The stability of cannabinoids was investigated at room
temperature. The QuantisalTM device pads were spiked
with cannabinoids and allowed to remain in the buffer for
1, 4, 12, or 24 h at room temperature prior freezing and
Table 3 Validation data for trueness, intraday and intermediate precisions, and linearity for THCCOOH, THCCOOH-gluc, THC-A, THC-gluc,
11-OH-THC, CBD, THC, and CBN obtained using the solid-phase extraction method
Validation criterion Levela THCCOOH THCCOOH-
gluc
THC-A THC-gluc 11-OH-
THC
CBD THC CBN
Trueness (%) 0.5 99.7 91.2 95.5 99.0 96.7 113.0 106.4 102.7
2 99.7 96.0 97.1 98.3 99.8 101.5 104.6 102.1
10 100.9 95.2 98.8 97.8 101.3 98.9 102.4 102.2
30 100.1 92.0 102.5 97.9 100.2 98.2 100.8 101.1
75 99.5 104.1 98.8 104.2 100.4 98.9 102.0 103.9
Intraday precision
(CV, %)
0.5 6.9 4.4 8.1 4.2 5.9 9.4 7.2 3.5
2 2.4 6.0 6.1 3.6 2.4 2.8 3.4 3.9
10 3.2 4.1 5.8 4.2 1.2 5.0 3.0 7.4
30 1.5 5.4 3.0 5.3 0.8 5.3 1.5 2.7
75 1.7 3.8 2.7 4.2 0.8 2.4 1.4 5.2
Intermediate precision
(CV, %)
0.5 5.2 20.5 9.4 6.9 10.1 12.3 5.9 6.5
2 1.4 6.3 6.0 1.5 0.4 8.4 3.8 4.3
10 2.3 5.2 8.0 1.7 0.1 1.5 2.2 4.0
30 0.5 5.6 4.1 3.8 0.5 2.6 1.1 2.1
75 1.5 6.0 3.4 5.4 1.1 2.1 2.2 5.0
Linearity
Slope (CV) 0.9965
(1.1 %)
1.0389
(3.6 %)
0.9954
(0.5 %)
1.0197
(2.2 %)
1.000
(0.4 %)
0.9863
(1.9 %)
1.0134
(2.6 %)
1.0025
(1.1 %)
y intercept (CV) 0.0538
(11.1 %)
-0.9038
(5.9 %)
0.0378
(8.1 %)
-0.0350
(6.4 %)
0.0018
(4.8 %)
0.0158
(13.6 %)
0.0751
(5.4 %)
0.0035
(15.5 %)
R2 0.9997 0.9967 0.9995 0.9996 0.9999 0.9987 0.9997 0.9994
LOD (ng/ml) 0.1 0.3 0.05 0.05 0.1 0.3 0.05 0.1
LOQ (ng/ml) 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5
a Fortified OF concentration (ng/ml)
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storing at -80 C. No obvious variation (\15 %) in the
peak area was observed over this time period. These results
demonstrate that cannabinoids are relatively stable in the
extraction buffer and that it is not necessary to incubate the
pad at room temperature for at least 4 h, as recommended
by the manufacturer for optimal cannabinoid extraction.
The stability of the cannabinoids after one or three
freeze–thaw cycles was also investigated. OF extracts were
injected into the LC–MS/MS system after one or three
freeze–thaw cycles, and the peak areas were compared to
those of samples analyzed immediately after spiking and
without any freezing. All cannabinoids were stable after
one freeze–thaw cycle, with the exception of THCCOOH-
gluc and CBN (exhibiting 17 and 13 % maximum loss,
respectively). In contrast, three freeze–thaw cycles resulted
in a considerable degradation of cannabinoids, with a mean
decrease of 30 % and a maximum loss of 52 % for CBN.
Analyses of authentic oral fluid samples
Data for the appearance and disappearance of cannabinoids
as a function of time in neat OF collected at home with the
QuantisalTM device are provided in Table 6. The LLE
method was used for the determination of THCCOOH,
whereas SPE was used for the analysis of all other can-
nabinoids. We detected THC at very high concentrations,
up to 11,887 ng/ml for subject 5, in the first OF specimens
obtained 10 min after the first inhalation of cannabis
smoke. All samples tested positive for THC at concentra-
tions in the range 2.8–128 ng/ml in the final OF specimen.
THC-A was also detected at relatively high levels with
peak concentrations ranging from 44 to 2031 ng/ml. As
observed with THC, all OF specimens tested positive for
THC-A. Interestingly, THC and THC-A exhibited the
highest concentrations in the first sample obtained 10 min
after inhalation. These results indicate that THC-A is not
completely transformed into THC by decarboxylation
during the smoking process, and it is also present in OF
primarily as a result of deposition in the oral cavity. CBD
and CBN were also found, but in much lower concentra-
tions. The time to reach the maximum level for CBD and
CBN was identical to that of THC and THC-A, suggesting
that their presence is also mainly due to the contamination
of the oral cavity during the inhalation. THCCOOH was
only detected in a few OF samples, and always at very low
concentrations. In contrast to the other cannabinoids, the
Table 4 Extraction efficiencies (SD) observed for the LC–MS/MS analysis of eight cannabinoids in spiked drug-free oral fluid samples at
different concentrations
Analyte SPE extraction efficiency (%, n = 4) LLE extraction efficiency (%, n = 4)
2 ng/ml 75 ng/ml 100 pg/ml 400 pg/ml 2 ng/ml 75 ng/ml
THCCOOH 39.8 (6.8) 34.2 (6.1) 34.9 (2.6) 36.7 (5.5) 46.7 (3.4) 46.5 (4.1)
THCCOOH-gluc 37.5 (3.6) 33.3 (4.5) – – – –
THC-A 38.1 (7.3) 32.7 (6.6) – – 44.3 (3.5) 40.0 (3.0)
THC-gluc 41.8 (5.0) 37.5 (5.8) – – – –
11-OH-THC 38.3 (5.8) 29.5 (5.2) – – 42.8 (1.6) 42.3 (2.6)
CBD 39.7 (8.8) 31.7 (6.0) – – 44.2 (1.2) 42.8 (2.9)
THC 28.8 (8.3) 26.6 (5.7) – – 39.8 (3.9) 39.6 (2.2)
CBN 38.3 (7.1) 28.2 (3.5) – – 43.4 (1.2) 47.1 (3.0)
Table 5 Matrix effects (SD) observed for eight cannabinoids in spiked drug-free oral fluid samples at different concentrations
Analyte SPE matrix effect (bias %, n = 4) LLE matrix effect (bias %, n = 4)
2 ng/ml 75 ng/ml 50 pg/ml 400 pg/ml 2 ng/ml 75 ng/ml
THCCOOH -31.4 (5.0) -28.8 (5.9) -33.8 (4.7) -31.6 (4.2) -29.5 (3.7) -21.2 (4.1)
THCCOOH-gluc -32.9 (4.7) -29.1 (3.3) – – – –
THC-A -2.4 (8.7) -1.6 (6.5) – – -12.1 (2.6) -9.3 (1.7)
THC-gluc -19.1 (6.8) -30.3 (4.3) – – – –
11-OH-THC -32.9 (4.4) -31.0 (4.0) – – -21.1 (3.4) -22.1 (2.9)
CBD -29.6 (5.2) -41.5 (3.5) – – -25.5 (3.1) -29.1 (1.8)
THC -45.5 (4.1) -53.1 (5.2) – – -38.9 (4.6) -39.3 (2.3)
CBN -49.0 (4.6) -39.7 (7.1) – – -32.5 (4.7) -31.8 (3.8)
Negative values indicate ion suppression, whereas positive values indicate ion enhancement
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time to reach its maximum level was delayed in four out of
five cases, from the first to the second, and even to the
fourth OF specimen taken after smoking. Because THC-
COOH is not known to be present in the joints and only
produced by animal metabolism, and also because its
kinetic in OF differs from other cannabinoids found in
cannabis, its presence is thought to result exclusively from
body metabolism. The low concentrations of THCCOOH
could only be measured using the LLE method. The con-
centrations ranged from the LOQ (80 pg/ml) to 2.4 ng/ml.
The LOD and LOQ of the SPE method were not high
enough to detect and measure this metabolite in the
majority of OF samples. Surprisingly, the more polar glu-
curonide conjugates were not found in the OF specimens of
the five cannabis smokers, except for the first volunteer for
whom traces of THCCOOH-gluc were found in three out of
seven samples. Several hypotheses can be presented to
explain these observations: a strong binding to plasma
proteins [44], poor diffusion into OF [45], a lack of
transport proteins, or the presence of degrading enzymes.
In the latter case, the presence of beta-glucuronidase
enzymes in OF [35–37] could explain the lack of detection
of THCCOOH-gluc and THC-gluc in OF. In agreement
with the assumption that glucuronide conjugates of can-
nabinoids are present in OF in significant amounts, a study
published in 2007 by Moore et al. [4] suggests that 48.2 %
of THCCOOH is glucuronidated in OF (estimated after
beta-glucuronidase treatment). In the same study, the
authors indicate that the concentration of THC in OF
remained nearly unchanged after treatment with beta-
glucuronidase. This result suggests that THC was poorly
conjugated at best. Similar observations were made with
the glucuronide conjugates of other drugs. For example,
oxazepam glucuronide and other benzodiazepine conju-
gates were found only in trace levels in OF [46]. A minor
but active THC metabolite, 11-OH-THC was also not
detected.
Assessment of chemical and enzymatic hydrolysis
of glucuronide conjugates of THC and THCCOOH
in oral fluid
The extent of hydrolysis of THC and THCCOOH glucu-
ronides and the resulting formation of free cannabinoids
were investigated under various incubation conditions.
These conditions were selected to distinguish between
nonenzymatic and enzyme-catalyzed degradation of glu-
curonidated cannabinoids. To assess the nonenzymatic
hydrolysis of conjugates, we incubated glucuronides in the
presence of heat-inactivated OF enzymes. We also inves-
tigated the extent of total hydrolysis (both uncatalyzed and
enzymatic) by incubating the glucuronides with an
untreated OF mix. The reaction media were diluted with
either water or an acetate buffer known to be optimal for
beta-glucuronidase activity. The relative concentrations of
substrates and products after 0, 0.5, 1, and 5 h are provided
in Table 7. A significant hydrolysis of THCCOOH-gluc
(*85 % after 5 h) was only observed with native OF.
THC-gluc was only mildly degraded (\30 %), suggesting
that this compound is much more resistant toward human
beta-glucuronidase action. This latter result confirms a
previous study of Watanabe et al. [47]. They demonstrated
that D8-THC-gluc is relatively resistant to degradation with
a maximum hydrolysis of 31.6 % with bacterial beta-
glucuronidase. Furthermore, Scheidweiler et al. [48] dem-
onstrated recently that in urine THC-gluc is more stable than
THCCOOH-gluc. Conversely, the decrease in the substrate
Table 6 Cannabinoid concentration in oral fluid as a function of
time before and after smoking a homemade joint
Subject Time
(min)
THCCOOH THC-
A
CBD THC CBN
1 -10 0.5 2.6 0.5 290 6.7
20 1.3 175 6.9 3120 165
40 2.4 41 4.3 1970 98
60 0.7 10 0.6 441 19
120 0.3 12 n.d. 232 6.4
210 0.4 6.6 n.d. 30 11
2 -10 n.d. 2.7 n.d. 5.9 n.d.
20 0.17 66 3.7 971 182
40 0.31 14 1.2 210 45
60 \0.08 2.2 0.9 37 2.8
120 \0.08 1.7 n.d. 33 2.7
210 n.d. \0.5 n.d. 22 2.0
3 -10 n.d. 1.0 n.d. 1.4 0.5
20 0.17 44 2.8 1060 212
40 0.14 10 2.1 627 37
60 \0.08 6.1 1.5 123 31
120 n.d. 1.0 \0.5 9 4.2
210 n.d. 0.7 n.d. 7 3.9
4 -10 n.d. 15 \0.5 13 \0.5
20 n.d. 45 7.3 196 4.3
40 0.51 19 2.5 84 1.8
60 0.35 6.8 \0.5 13 3.1
120 0.08 6.1 \0.5 8.2 2.4
210 n.d. 5.6 n.d. 2.8 \0.5
5 -10 n.d. 279 n.d. 475 2.5
10 n.d. 2031 5.0 11,887 79
20 \0.08 692 2.1 2858 44
40 0.15 353 \0.5 1041 10
60 0.31 763 n.d. 1396 8.3
120 0.18 436 n.d. 729 5.7
300 \0.08 158 n.d. 128 0.8
Concentrations of cannabinoids in neat oral fluid are expressed in ng/ml
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concentration coincided with a substantial increase in
THCCOOH and in THC. The buffering of the reaction
medium significantly increased the extent of glucuronide
degradation. The enzymatic degradation of THCCOOH-
gluc increased from 5.1 pmol in OF ? water to 8.5 pmol
in OF ? buffer for 1.0 ml of OF volume (i.e., a 67 %
increase). Under various conditions, the absence of native
OF in the reaction medium significantly diminished the
hydrolysis of glucuronides. OF proteins and their confor-
mation (native or denaturated) certainly have a significant
influence on the stability and extractability of cannabi-
noids. In addition to mucins and enzymes, OF contains
many proteins including albumin. According to Wang et al.
[49], human albumin exists in a wide range of concentra-
tions in saliva (5–45 mg/l). In 2002, Skopp et al. [44]
showed that the addition of albumin in protein-free samples
prior to the extraction step increases the recovery of free
and conjugated cannabinoids. Furthermore, this protein is
known to bind with the majority of the cannabinoids [50].
The binding of cannabinoids to albumin and other proteins
could stabilize and protect glucuronide conjugates from
degradation. Finally, the pH of the incubation medium
should also have an influence. Indeed the chemical
hydrolysis of glucuronides is enhanced at pH 7 (inactivated
OF ? water) compared to pH 4.5 (inactivated OF ? ace-
tate buffer). Based on the comparison of the extent of
THCCOOH-gluc degradation after incubation with native
or inactivated OF, we can assume that approximately 60 %
of the THCCOOH-gluc was enzymatically degraded,
whereas only 40 % was chemically hydrolyzed. These
results confirm the presence of beta-glucuronidase activity
in OF, and may partly explain the difficulty to detect glu-
curonide conjugates in this matrix. THC-gluc was found to
be much less susceptible to enzymatic hydrolysis than
THCCOOH-gluc, which contains a more labile ester bond.
Conclusions
To our knowledge, this work represents the first analytical
method developed for the detection and quantification of a
broad range of cannabinoids, including a THC precursor
and two glucuronide conjugates, in oral fluid by LC–MS/
MS. This method utilizes a new KinetexTM core–shell
column combined with an API 5000TM triple quadrupole
system, and was successfully applied for the determination
of cannabinoids in OF specimens collected from five dif-
ferent cannabis smokers. The collection of the OF was
Table 7 Comparison of
cannabinoid glucuronide
degradation in native and
inactivated oral fluid (OF) as
well as in aqueous and buffered
(pH 4.5) solutions
Concentrations of THCCOOH,
THCCOOH-gluc, THC and
THC-gluc are expressed in
pmol/ml of reaction mixture
–, not available
Sample Time (h) THCCOOH THCCOOH-gluc THC THC-gluc
OF ? water 0 2.13 10.11 0.40 9.19
0.5 2.43 8.37 2.27 8.34
1 3.93 5.60 2.97 7.46
5 7.94 1.50 – 6.71
OF ? acetate buffer 0 1.45 10.48 0.55 8.88
0.5 2.62 8.82 0.79 8.03
1 4.05 6.43 1.94 7.78
5 7.35 2.01 – 7.48
Inactivated OF ? water 0 0.90 10.51 0.45 8.79
0.5 0.86 10.09 0.34 8.45
1 0.90 9.68 0.38 8.30
5 0.92 7.00 0.39 8.24
Inactivated OF ? acetate buffer 0 0.65 10.95 0.43 8.76
0.5 0.53 10.67 0.40 7.95
1 0.54 10.91 0.36 8.19
5 0.42 11.20 0.39 8.17
Water ? water 0 \LOQ 8.73 \LOQ 3.14
0.5 \LOQ 7.96 \LOQ 3.03
1 \LOQ 6.30 \LOQ 3.09
5 \LOQ 5.86 \LOQ 3.02
Water ? acetate buffer 0 \LOQ 8.49 \LOQ 3.31
0.5 \LOQ 5.85 \LOQ 3.37
1 \LOQ 5.48 \LOQ 3.49
5 \LOQ 5.45 \LOQ 3.07
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simplified with the use of a QuantisalTM collection device.
THC-gluc was not detected in real OF specimens, whereas
THCCOOH-gluc was found only at trace levels in a few
samples. Moreover, our experiments suggest that THC-
COOH-glucuronide could be hydrolyzed by beta-glucu-
ronidase enzymes present in the OF. Liquid–liquid
extraction proved to be the most efficient method for
THCCOOH detection provided that THCCOOH-glucuro-
nide and THC-glucuronide determination is not required.
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